Pfizer pill reduces progression by 81% for a rare type of lung cancer
60% of patients who received Lorbrena were alive and had not seen their tumors progress in the five years of a study presented at ASCO. May ...Read More
An ASCO preview & another Duchenne trial failure
And more pronunciation struggles! May 31, 2024 Check out STAT+ Sponsored By W hich presentations are worth catching at ASCO this weekend? ...Read More
Mental health inequities could cost $1.3T in 2040
The latest stories trending on MedCity News. ...Read More
Subscribe to:
Posts
(
Atom
)